View Post

Building “boot camps” for immune cells near tumors

In In The News by Barbara Jacoby

By: Alyssa Kneller From: Redington Newsdesk Novartis is collaborating with @wyssinstitute and @DanaFarber to develop devices with #cancer-fighting potential A new wave of therapies is unleashing the body’s immune system on cancer, significantly extending lives. These agents, however, don’t work for everyone, so scientists are exploring new approaches that might enable immunotherapies to more effectively combat tumors. One idea, born …

View Post

Pfizer, Novartis agree UK price cuts for new breast cancer drugs

In In The News by Barbara Jacoby

From: reuters.com Pfizer and Novartis have agreed price cuts for their rival breast cancer drugs Ibrance and Kisqali to ensure they can be used routinely within Britain’s state-funded health service. The National Institute for Health and Care Excellence (NICE), the country’s cost-effectiveness agency, said on Thursday the two drugs were being recommended despite uncertainty about how long they extend overall …

View Post

Breakthrough cancer drug could be astronomical in price

In In The News by Barbara Jacoby

By: Liz Szabo, Kaiser Health News From: usatoday.com A new leukemia drug being hailed by doctors as a breakthrough could prove among the most expensive therapies ever on the market: For a single treatment, the price is expected to reach hundreds of thousands of dollars. “It is a revolutionary treatment,” said Dr. Prakash Satwani, a pediatric hematologist at NewYork-Presbyterian/Columbia University Medical Center, …

View Post

Novel cancer treatment wins endorsement of FDA advisers

In In The News by Barbara Jacoby

By: Laurie McGinley From: washingtonpost.com Food and Drug Administration advisers on Wednesday enthusiastically endorsed a first-of-its-kind cancer treatment that uses patients’ revved-up immune cells to fight the disease, concluding that the therapy’s benefits for desperately ill children far outweigh its potentially dangerous side effects. The unanimous recommendation from the Oncologic Drugs Advisory Committee means the treatment could be approved by the FDA …

View Post

Novartis receives FDA approval for first-of-its-kind Kisqali® Femara® Co-Pack for initial treatment of HR+/HER2- advanced or metastatic breast cancer

In In The News by Barbara Jacoby

From: PR Newswire — Physicians now have the option of prescribing Kisqali and Femara together in one convenient co-pack — Co-Pack allows patients ability to obtain Kisqali and Femara with a single co-pay — Approval comes less than two months after Kisqali received US FDA approval  Novartis announced today that the US Food and Drug Administration (FDA) has approved the …

View Post

First come, first served: Novartis finalizes CAR-T application, claims priority review

In In The News by Barbara Jacoby

By: Juliet Preston From: MedCity News Novartis has made good on its promise to submit a biologics license application (BLA) for its lead CAR-T candidate in the first quarter of the fiscal year. With two days to spare, no less. According to a statement released on Wednesday, the FDA has accepted the submission and granted Novartis a priority review. That …

View Post

Cota Healthcare Announces Major Multi-Year Collaboration With Global Pharmaceutical Leader To Advance Innovative Therapies For Breast Cancer Patients

In In The News by Barbara Jacoby

Cota Healthcare, the leading data and technology platform for value-based precision medicine, today announced the signing of a major, multi-year collaboration with Novartis Pharmaceuticals Corporation to help improve clinical and cost outcomes for breast cancer patients. As part of this agreement, which expands significantly on the previous announced collaboration entered into January 2016, teams from across Novartis Pharmaceuticals Corporation will …

View Post

Novartis chases rivals with next wave of cancer immunotherapy

In In The News by Barbara Jacoby

From: reuters.com Novartis (NOVN.S), lagging some other big drugmakers in the first wave of immunotherapy drugs that are revolutionizing cancer treatment, hopes to catch up by focusing on the next wave of immune system-boosting medicines. Setting out its research objectives in slides for a press conference on Wednesday, it said it aimed for “a leadership position in oncology” by focusing …

View Post

Encouraging Results For Ribociclib In Advanced Breast Cancer

In In The News by Barbara Jacoby

By: Elaine Schattner From: forbes.com At the European Society for Medical Oncology (ESMO) Congress this week, investigators presented data for a new and potentially important drug, ribociclib (Novartis). This oral medication is clearly active in hormone receptor-positive (ER+ or PR+) breast cancer. The findings of the MONALEESA trial were published in the NEJM. The main result is that for the most …

View Post

Novartis survey published in The Breast Journal reveals major gaps in treatment discussions between metastatic breast cancer patients and doctors

In In The News by Barbara Jacoby

89% of metastatic breast cancer patients surveyed feel it’s important to discuss a long-term treatment “roadmap” with their doctor at initial diagnosis, yet 43% report not having that conversation1 Patients seek comprehensive dialogue with oncologists to understand treatment options and quality of life issues throughout the course of their disease1   Results led to a community-endorsed personalized discussion guide to help …